<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045913</url>
  </required_header>
  <id_info>
    <org_study_id>Yonsei University</org_study_id>
    <nct_id>NCT03045913</nct_id>
  </id_info>
  <brief_title>Genoss DES Prospective Multicenter Registry</brief_title>
  <official_title>Prospective Multicenter Observational Study for Evaluating Efficacy and Safety of GENOSS Sirolimus-eluting Stent in Patients With Coronary Artery Disease (GENOSS Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yoon Junghan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genoss Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is a clinical post-market evaluation of the Genoss DES in subjects requiring
      coronary revascularization with Drug Eluting Stents (DES).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) is the main stream of treatment of coronary artery
      disease. Drug-eluting stents (DES) have dramatically reduced the rates of restenosis and
      target lesion revascularization (TLR) compared with bare-metal stents (BMS). Newer-generation
      DES with a durable polymer such as Xience (Abbott, US) and Resolute (Medtronic, US) were
      widely used. However, the concern about late stent thrombosis due to hypersensitivity
      reaction from the polymer is still existed. Recently, DES with a biodegradable polymer such
      as Biomatrix (Biosensors, Switzerland), Nobori (Terumo, Japan), Orsiro (Biotronik,
      Switzerland), and Synergy (Boston Scientific, US) was rapidly adopted and it is expected to
      reduce the late stent thrombosis.

      Recently, new biodegradable DES with thin struts was developed in South Korea. The Genoss DES
      (Genoss, Korea) has an L-605 cobalt chromium (CoCr) platform with a strut thickness of about
      70 µm and the stent is coated a combination of Sirolimus drug with concentration of
      1.15µg/mm2 and an abluminal biodegradable PLA and PLGA polymers.

      This study is conducted to evaluate efficacy and safety of Genoss DES in the treatment of
      patients with coronary artery disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Device-oriented composite end point (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death, any myocardial infarction not clearly attributable to a nontarget vessel, and clinically indicated target-lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite end point</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of any death, any myocardial infarction, and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction not clearly attributable to a nontarget vessel</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target-lesion revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target-vessel revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC defined stent thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Genoss DES</arm_group_label>
    <description>Subject implanted Genoss DES for coronary artery disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Genoss DES</intervention_name>
    <description>The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.</description>
    <arm_group_label>Genoss DES</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All-comers patient population with all subjects requiring coronary revascularization with a
        Drug Eluting Stent (DES)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥ 19 years

          -  Subject implanted Genoss DES within 1 month

          -  Subject has signed informed consent for data release

          -  Subject is geographically stable and willing to participate at all follow-up
             assessments

        Exclusion Criteria:

          -  Subject did not sign informed consent for data release

          -  Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other
             anticoagulation / antiplatelet therapy required for PCI, cobalt chromium, Sirolimus or
             contrast media

          -  Pregnancy

          -  Subject with life expectancy less than 12 months

          -  Subject with cardiogenic shock

          -  Planned surgery within 12 months of PCI unless dual antiplatelet therapy will be
             maintained

          -  Currently participating in another study and primary endpoint is not reached yet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junghan Yoon, MD, PhD</last_name>
    <phone>+82-33-741-1219</phone>
    <email>jyoon@yonsei.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Jin Yoon, MD</last_name>
    <phone>+82-33-741-1219</phone>
    <email>younyj@yonsei.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon</state>
        <zip>220060</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junghan Yoon, MD, PhD</last_name>
      <phone>+82-33-741-0906</phone>
      <email>jyoon@yonsei.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young Jin Youn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junghan Yoon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung-Hwan Lee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byung-Su Yoo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jang-Young Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min-Soo Ahn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung-Gyun Ahn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji-Hyun Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Woo-Cheol Kwon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Yoon Junghan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Observational registry</keyword>
  <keyword>All-comers open label registry</keyword>
  <keyword>Genoss DES</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Stenting</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

